<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384994</url>
  </required_header>
  <id_info>
    <org_study_id>PARLIM</org_study_id>
    <nct_id>NCT01384994</nct_id>
  </id_info>
  <brief_title>Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. med. Volker Heinemann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 50% of patients with colorectal cancer (CRC) develop liver metastasis during the course&#xD;
      of their disease. In 30-40% of patients metastasis is confined to the liver. In these&#xD;
      patients R0-resection of metastases may contribute to marked improvement of overall survival.&#xD;
      Primary resection of liver metastasis is possible in about 15-20% of patients (Scheele 2005,&#xD;
      Petrelli 2005). Recent studies indicate that perioperative chemotherapy may improve survival&#xD;
      after resection of liver metastases (Portier 2007, Nordlinger 2007). Nevertheless, there is&#xD;
      evidence that 70-80% of patients have recurrent disease after resection of liver metastasis.&#xD;
      Stratification for the risk of recurrence may be performed using the FONG-score (Fong 1999).&#xD;
&#xD;
      This study is designed to investigate the efficacy of postoperative chemotherapy combined&#xD;
      with an anti-EGFR treatment using panitumumab.&#xD;
&#xD;
      The majority of patients present to the surgeon after chemotherapeutic pretreatment with&#xD;
      various not necessarily standardized regimens. Also postoperative therapy after resection of&#xD;
      liver metastasis is not a clearly defined standard of care in Germany.&#xD;
&#xD;
      Based on the study by Nordlinger et al. an oxaliplatin-based regimen is chosen for&#xD;
      postoperative therapy (Nordlinger 2008). For reasons of practicability mFOLFOX6 was selected&#xD;
      as the chemotherapy backbone for additive treatment (Allegra 2010).&#xD;
&#xD;
      Also, there is evidence that the combination of FOLFOX with panitumumab is associated with&#xD;
      enhanced antitumor activity (Douillard et al. ESMO 2009). The experimental treatment arm will&#xD;
      therefore evaluate the combination of FOLFOX plus panitumumab. Since in colorectal cancer&#xD;
      monoclonal antibodies directed against the EGFR are not active in KRAS mutant patients, the&#xD;
      experimental arm including panitumumab will only be performed in KRAS wild-type patients&#xD;
      (Amado 2008).&#xD;
&#xD;
      The planned study aims to assess the efficacy of postoperative therapy with FOLFOX plus&#xD;
      panitumumab followed by maintenance with panitumumab for 3 months in KRAS wild-type patients,&#xD;
      compared to the historical data for standard FOLFOX chemotherapy alone, which are verified by&#xD;
      a randomised control group without the antibody. (Figure 1: Study Design).&#xD;
&#xD;
      The study will allow preoperative treatment with regimens such as FOLFIRI, XELIRI, FOLFOX or&#xD;
      XELOX +/-bevacizumab or +/- cetuximab. However, only those patients will be considered&#xD;
      eligible who did not progress during preoperative therapy.&#xD;
&#xD;
      After surgery, a treatment-free interval of at least 4 weeks, but no longer than 8 weeks will&#xD;
      be granted.&#xD;
&#xD;
      KRAS-wild-type patients (60% of all pts) will then be randomized in a 2:1 ratio to an&#xD;
      experimental arm with FOLFOX + panitumumab or to a reference arm with FOLFOX alone.&#xD;
      Combination treatment will be performed for a duration of 3 months, after which patients in&#xD;
      the experimental arm will receive maintenance therapy with panitumumab for further 3 months.&#xD;
      In the reference arm, treatment will, however, be ended after 3 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability and side effects</measure>
    <time_frame>approximate 6 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years after randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>KRAS Wildtype</condition>
  <condition>After Resection of Liver Metastases</condition>
  <arm_group>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>400 mg/m2, 2h infusion, d1, q2w</description>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m2 bolus iv, d1, q2w</description>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>2400 mg/m2 46-h infusion, d1-2, q2w</description>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m2 d1, q2w</description>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>6 mg/kg BW every 2 weeks</description>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks</description>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>400 mg/m2, 2-h infusion, d1, q2w</description>
    <arm_group_label>FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m2 bolus iv, d1, q2w</description>
    <arm_group_label>FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>2400 mg/m2 46-h infusion, d1-2, q2w</description>
    <arm_group_label>FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m2 d1, q2w</description>
    <arm_group_label>FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has provided written informed consent.&#xD;
&#xD;
          -  R0-resection of liver metastasis, at least four weeks but not longer than 8 weeks ago.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of metastatic colorectal cancer confined to the&#xD;
             liver&#xD;
&#xD;
          -  KRAS-wildtype of the tumor&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Females with child-bearing potential must use adequate contraceptive measures&#xD;
&#xD;
          -  Exclusion of pregnancy&#xD;
&#xD;
          -  Relevant toxicities of previous treatments must have subsided&#xD;
&#xD;
          -  Magnesium &gt;= lower limit of normal; Calcium &gt;= lower limit of normal&#xD;
&#xD;
          -  Normal cardiac function demonstrated by ECG and echocardiogram (LVEF ≥ 55%)&#xD;
&#xD;
               -  No symptomatic congestive heart failure&#xD;
&#xD;
               -  No unstable angina pectoris&#xD;
&#xD;
               -  No cardiac arrhythmia&#xD;
&#xD;
          -  Adequate organ function as defined by Table 1:&#xD;
&#xD;
               -  Hematologic: ANC (absolute neutrophil count) &gt;= 1.5 G/L, Leucocytes &gt; 3.0 G/L,&#xD;
                  Hemoglobin &gt;= 9 g/dL, Platelets &gt;= 100 G/L&#xD;
&#xD;
               -  Hepatic: Albumin &gt;= 2.5 g/dL, Serum bilirubin &lt;= 2 mg/dL, AST and ALT &lt;= 3 x ULN&#xD;
&#xD;
               -  Renal: Serum Creatinine &lt;= 1.5 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known manifestations of metastatic disease&#xD;
&#xD;
          -  Progression during preoperative treatment&#xD;
&#xD;
          -  Missing KRAS mutation status of the tumor&#xD;
&#xD;
          -  Contraindication against therapy with 5-fluorouracil/ folinic acid or oxaliplatin&#xD;
&#xD;
          -  Known intolerability of panitumumab&#xD;
&#xD;
          -  Known DPD deficiency&#xD;
&#xD;
          -  Polyneuropathy &gt; grade 1 (NCI-CTCv4) which precludes the use of oxaliplatin&#xD;
&#xD;
          -  Evidence of ascites or cirrhosis&#xD;
&#xD;
          -  Patient is pregnant or lactating or planning to become pregnant within 6 months after&#xD;
             end of treatment&#xD;
&#xD;
          -  Subject (male or female) is not willing to use highly effective methods of&#xD;
             contraception (per institutional standard) during treatment and for 6 months (male or&#xD;
             female) after the end of treatment&#xD;
&#xD;
          -  Has had a major surgical procedure, open biopsy, or significant traumatic injury&#xD;
             within 28 days prior to study enrolment, or there is an anticipated need for major&#xD;
             surgical procedure during the course of the study&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (including myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) &lt;= 1 year before enrolment/randomization&#xD;
&#xD;
          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan&#xD;
&#xD;
          -  Has a concurrent disease or condition that would make the subject inappropriate for&#xD;
             study participation or would interfere with the subject's safety.&#xD;
&#xD;
          -  Has any psychological, familial, sociological, or geographical conditions that do not&#xD;
             permit compliance with the protocol.&#xD;
&#xD;
          -  Requires concurrent cancer therapy (chemotherapy, radiation therapy, biologic therapy,&#xD;
             immunotherapy, or hormonal therapy) while on study.&#xD;
&#xD;
          -  Requires concurrent treatment with an investigational agent, participation in another&#xD;
             clinical trial, or any specifically prohibited medication while on study.&#xD;
&#xD;
          -  Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to 5-fluorouracil, folinic acid, oxaliplatin, or panitumumab.&#xD;
&#xD;
          -  Other active malignancy&#xD;
&#xD;
          -  Known alcohol abuse or drug addiction&#xD;
&#xD;
          -  Incapability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Volker Heinemann, Prof. Dr. med.</last_name>
    <phone>+49 89 7095</phone>
    <phone_ext>0</phone_ext>
    <email>volker.heinemann@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clemens Gießen, Dr. med.</last_name>
    <phone>+49 89 7095</phone>
    <phone_ext>0</phone_ext>
    <email>clemens.giessen@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ludwig-Maximilians - University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Heinemann, Prof. Dr. med.</last_name>
      <phone>+49 89 7095</phone>
      <phone_ext>0</phone_ext>
      <email>volker.heinemann@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Clemens Giessen, Dr. med.</last_name>
      <phone>+49 89 7095</phone>
      <phone_ext>0</phone_ext>
      <email>clemens.giessen@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Volker Heinemann, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>July 5, 2012</last_update_submitted>
  <last_update_submitted_qc>July 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Volker Heinemann</investigator_full_name>
    <investigator_title>Sponsor Delegatated Person</investigator_title>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>PARLIM</keyword>
  <keyword>KRAS Wildtype</keyword>
  <keyword>Liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

